Buy Like Buffett
Watchlist

Flagship explainer

What drives BioXcel Therapeutics, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity74%Tax burden100%net income ÷ pretax incomeInterest burden139%pretax ÷ operating incomeOperating margin−7860%operating income ÷ revenueAsset turnover0.02×revenue ÷ average assetsEquity multiplier-0.44×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$69.9MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Income before tax−$69.9MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Operating income−$50.5MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
$642000FY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Ending assets$44.9MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Beginning assets$38.3MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
−$95.5MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
−$93.1MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Source: · event Dec 31, 2025 · retrieved Sep 19, 2026 · annual-row source set
Embed this chart

View the full BioXcel Therapeutics, Inc. analysis at Buy Like Buffett

BTAIQ dupont explainer — Buy Like Buffett · Buy Like Buffett